• We are catalysts for innovation, commercialising next-generation technologies developed by

    The University of Manchester’s world-class research base





    • £360m+ invested by venture funders

    • 40+ spin-out companies created

    • 7,500+ licences and IP partnerships concluded

    • 4,000+ invention disclosures received

    • £115m+ IP and R&D revenue generated for the University







  • We are catalysts for innovation, commercialising next-generation technologies developed by The University of Manchester’s world-class research base





    • £300m+ invested by venture funders since 2004

    • 40+ spin-out companies created

    • 4,800+



      licences and IP partnerships concluded

    • 3,700+ invention disclosures received

    • 1,300+ jobs generated across various industry sectors

    • £105m+ IP and R&D revenue generated for the University


Archive for September, 2014

University of Manchester spin-out co-founder voted the Most Influential Thinker in HR

University of Manchester spin-out co-founder Professor Sir Cary Cooper of Robertson Cooper Ltd has been voted the Most Influential Thinker in HR 2014, in a new poll of UK HR Directors for HR Magazine.

The award, nominated by all members of the HR community in UK business, recognises Cary’s contribution, working with businesses in the field of health and wellbeing, as Founder of wellbeing experts Robertson Cooper and as Professor of Organisational Health and Psychology at Lancaster University.

Voted at number 2 in 2013, Cary has risen to the top spot, holding off Peter Cheese, the CEO of the Chartered Institute of Personnel and Development.

Professor Sir Cary was knighted this year for services to social sciences and has previously filled many roles including Lead Scientist on the Foresight Review of Mental Capital and Well-Being and Chair of the Global Agenda Council on Chronic Disease of the World Economic Forum. He is currently the Chair of the Academy of Social Sciences and President of RELATE.

Professor Sir Cary comments: “It is a great honour to be considered by the leading HR Directors in the UK as an important HR thought leader, and an acceptance of the importance of health and wellbeing in British business.”

Clive Rowland, CEO of UMI3 Ltd, The University of Manchester’s innovation company, comments:” The University is active in intellectual property commercialisation and knowledge transfer work across the whole campus, not only in so-called ‘high-tech’ fields, and Robertson Cooper is a successful world-leading example of this. I am delighted that Sir Cary has been recognised in this way and it is well deserved recognition for both the very hard work and the highly positive commitment that he gives to his profession.”

Find out more about Robertson Cooper at www.robertsoncooper.com

Twitter: @gooddayatwork

F2G Limited announces a major funding award from the Technology Strategy Board’s Biomedical Catalyst

The prestigious £1.4 million award will expedite the development of F2G’s novel IV/oral systemic antifungal F901318. The Biomedical Catalyst project will focus on the oral Phase I clinical development of F901318 and supporting studies, and will allow the company to accelerate its clinical development activities.

F901318 is being developed by F2G as an IV and oral therapy to treat invasive aspergillosis and other life- threatening fungal infections and is a new class of antifungal acting against a new cellular target. The discovery and development of F901318 represents a major advance in the treatment of serious fungal disease as currently there are very limited treatment options and resistance is becoming a serious problem. F901318 is highly active against all known azole-resistant aspergilli.

F2G Limited today announces commencement of a Phase 1 single ascending dose study of a novel antifungal agent

F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/ oral systemic antifungal (F901318) with the commencement of a Phase I clinical study. This study initiates the IV Phase I clinical development of F901318 with the oral programme expected to commence in the near future.

F901318 is being developed by F2G to treat invasive aspergillosis and other life-threatening fungal infections and is of a novel class of antifungals acting against a new cellular target. The discovery and development of F901318 represents a major advance in the treatment of serious fungal disease as currently there are very limited treatment options and resistance to existing drugs is becoming a serious problem. F901318 is highly active against all known azole-resistant aspergilli.

CONTACT US